Floatz logo

SEVIPROTIMUT-L

Relapsed or Refractory Hodgkin Lymphoma

Affimed GmbHvaccinePhase 2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Relapsed or Refractory Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
M-SYMPATHOL
Affimed GmbH
Phase 2CCC
shr2554
Chinese PLA General Hospital
Phase 1/2CCC
Shr-1701
Chinese PLA General Hospital
Phase 1/2CCC
Edicotinib
Janssen Research & Development, LLC
Phase 1C

Same molecule, other indications

SEVIPROTIMUT-L is also rated in:

Peripheral T Cell LymphomaDormant
CC
Indicative ·
43 / 100
View asset →
melanomaDormant
CC
Indicative ·
43 / 100
View asset →
Non Hodgkin LymphomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →